Literature DB >> 20809480

The effect of salvage therapy on survival in a longitudinal study with treatment by indication.

Edward H Kennedy1, Jeremy M G Taylor, Douglas E Schaubel, Scott Williams.   

Abstract

We consider using observational data to estimate the effect of a treatment on disease recurrence, when the decision to initiate treatment is based on longitudinal factors associated with the risk of recurrence. The effect of salvage androgen deprivation therapy (SADT) on the risk of recurrence of prostate cancer is inadequately described by the existing literature. Furthermore, standard Cox regression yields biased estimates of the effect of SADT, since it is necessary to adjust for prostate-specific antigen (PSA), which is a time-dependent confounder and an intermediate variable. In this paper, we describe and compare two methods which appropriately adjust for PSA in estimating the effect of SADT. The first method is a two-stage method which jointly estimates the effect of SADT and the hazard of recurrence in the absence of treatment by SADT. In the first stage, PSA is predicted in the absence of SADT, and in the second stage, a time-dependent Cox model is used to estimate the benefit of SADT, adjusting for PSA. The second method, called sequential stratification, reorganizes the data to resemble a sequence of experiments in which treatment is conditionally randomized given the time-dependent covariates. Strata are formed, each consisting of a patient undergoing SADT and a set of appropriately matched controls, and analysis proceeds via stratified Cox regression. Both methods are applied to data from patients initially treated with radiation therapy for prostate cancer and give similar SADT effect estimates.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809480      PMCID: PMC2962719          DOI: 10.1002/sim.4017

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

1.  Causal effect models for realistic individualized treatment and intention to treat rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

2.  A comparison of smoothing techniques for CD4 data measured with error in a time-dependent Cox proportional hazards model.

Authors:  P Bycott; J Taylor
Journal:  Stat Med       Date:  1998-09-30       Impact factor: 2.373

3.  Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia.

Authors:  N N Stone; S J Clejan
Journal:  J Androl       Date:  1991 Nov-Dec

4.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

Review 5.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

6.  Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.

Authors:  C J Tyrrell; L Denis; D Newling; M Soloway; K Channer; I D Cockshott
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

7.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

Authors:  W U Shipley; H D Thames; H M Sandler; G E Hanks; A L Zietman; C A Perez; D A Kuban; S L Hancock; C D Smith
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

8.  Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.

Authors:  A Gray; H A Feldman; J B McKinlay; C Longcope
Journal:  J Clin Endocrinol Metab       Date:  1991-11       Impact factor: 5.958

Review 9.  Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Authors:  B Nair; T Wilt; R MacDonald; I Rutks
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

Authors:  G K Zagars; A C von Eschenbach
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

View more
  16 in total

1.  Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation.

Authors:  Mbéry Sène; Jeremy Mg Taylor; James J Dignam; Hélène Jacqmin-Gadda; Cécile Proust-Lima
Journal:  Stat Methods Med Res       Date:  2014-05-20       Impact factor: 3.021

2.  Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies.

Authors:  Mohammad Ehsanul Karim; John Petkau; Paul Gustafson; Robert W Platt; Helen Tremlett
Journal:  Stat Methods Med Res       Date:  2016-09-21       Impact factor: 3.021

3.  Joint mixed-effects models for causal inference with longitudinal data.

Authors:  Michelle Shardell; Luigi Ferrucci
Journal:  Stat Med       Date:  2017-12-04       Impact factor: 2.373

4.  Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.

Authors:  Jincheng Shen; Lu Wang; Jeremy M G Taylor
Journal:  Biometrics       Date:  2016-11-28       Impact factor: 2.571

5.  Long-term opioid use after bariatric surgery.

Authors:  Matthew L Maciejewski; Valerie A Smith; Theodore S Z Berkowitz; David E Arterburn; Katharine A Bradley; Maren K Olsen; Chuan-Fen Liu; Edward H Livingston; Luke M Funk; James E Mitchell
Journal:  Surg Obes Relat Dis       Date:  2020-05-07       Impact factor: 4.734

6.  Comparison of methods for estimating the effect of salvage therapy in prostate cancer when treatment is given by indication.

Authors:  Jeremy M G Taylor; Jincheng Shen; Edward H Kennedy; Lu Wang; Douglas E Schaubel
Journal:  Stat Med       Date:  2013-07-03       Impact factor: 2.373

7.  Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Paul B Romesser; Xin Pei; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Yoshiya Yamada; Michael J Zelefsky
Journal:  J Urol       Date:  2015-07-10       Impact factor: 7.450

8.  A Framework for Treatment Decision Making at Prostate Cancer Recurrence.

Authors:  Jane M Lange; Bruce J Trock; Roman Gulati; Ruth Etzioni
Journal:  Med Decis Making       Date:  2017-05-31       Impact factor: 2.583

9.  Bariatric Surgery and Long-term Durability of Weight Loss.

Authors:  Matthew L Maciejewski; David E Arterburn; Lynn Van Scoyoc; Valerie A Smith; William S Yancy; Hollis J Weidenbacher; Edward H Livingston; Maren K Olsen
Journal:  JAMA Surg       Date:  2016-11-01       Impact factor: 14.766

10.  Real-time individual predictions of prostate cancer recurrence using joint models.

Authors:  Jeremy M G Taylor; Yongseok Park; Donna P Ankerst; Cecile Proust-Lima; Scott Williams; Larry Kestin; Kyoungwha Bae; Tom Pickles; Howard Sandler
Journal:  Biometrics       Date:  2013-02-04       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.